Anti-PD-1 antibody therapy for epithelial skin malignancies
An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study)

Maki Ishii, BA, Ikuko Hirai, MD, PhD, Keiji Tanese, MD, PhD, Takayuki Fusumae, MD, Yoshio Nakamura, MD, PhD, Keitaro Fukuda, MD, PhD, Hiroshi Uchi, MD, PhD, Kenji Kabashima, MD, PhD, Atsushi Otsuka, MD, PhD, Kenji Yokota, MD, PhD, Naoya Yamazaki, MD, PhD, Naoya Yamazaki, MD, PhD, Kenjiro Namikawa, MD, PhD, Taku Fujimura, MD, PhD, Tatsuya Takenouchi, MD, PhD, Yuki Yamamoto, MD, PhD, Mana Nishiguchi, MD, Yasunori Sato, PhD, Masayuki Amagai, MD, PhD, Takeru Funakoshi, MD, PhD

Abstract
Introduction: Malignant cutaneous epithelial tumors comprise various skin malignancies originating from the cutaneous epithelium, including cutaneous squamous cell carcinoma, basal cell carcinoma, and malignant cutaneous adnexal tumors. Treatment options are limited, as the rarity of these tumors, especially among Asians, renders well-controlled clinical trials extremely challenging to conduct. Thus, we designed a clinical trial to evaluate the efficacy and safety of the anti-programmed cell death-1 (PD-1) monoclonal antibody nivolumab in patients with metastatic cutaneous squamous cell carcinomas and other rare metastatic cutaneous epithelial tumors.

Methods and analysis: This is an open-label, single-arm, multicenter, phase 2 clinical trial involving patients with metastatic malignant cutaneous epithelial tumors. Nivolumab (480mg) will be administered intravenously every 4 weeks for a maximum of 26 doses. The primary outcome of the study will be the response rate based on response evaluation criteria in solid tumors, version 1.1. Assuming a null hypothesis of a response rate ≤5% and an alternative hypothesis of a 25% response rate, a minimum of 26 patients are required to achieve a 5% two-sided type I error and 80% power based on the exact binomial distribution. Finally, a target cohort size of 30 patients was determined as some patient dropout will be expected.

Discussion: This is the first phase 2 clinical trial evaluating the efficacy and safety of the PD-1 inhibitor nivolumab in Asian patients with metastatic malignant cutaneous epithelial tumors. The findings of the study will contribute to the development of novel treatment approaches for patients with rare cutaneous malignancies, which remains an unmet clinical need.

Trial registration: Registry number: JRCT 2031190048

Abbreviations: ALT = alanine aminotransferase, AST = aspartate aminotransferase, BCC = basal cell carcinoma, CD = cluster of differentiation, cSCC = cutaneous squamous cell carcinoma, CTLA = cytotoxic T-Lymphocyte associated protein, ECOG = Eastern cooperative oncology group, eGFR = estimated glomerular filtration rate, EMPD = extramammary Paget’s disease, FDA = U.S. Food and Drug Administration, HBsAg = hepatitis B surface antigen, HCV-Ab = hepatitis C antibody, HER2 = epidermal growth factor receptor
1. Introduction

Malignant cutaneous epithelial tumors, also referred to as non-melanoma skin cancer (NMSC), are common human neoplasms arising from the epidermis or cutaneous appendages. These include basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), extramammary Paget's disease (EMPD), and several other skin adnexal carcinomas. Of these, BCC and cSCC are the most common forms, accounting for 75% to 80% and 20% to 25% of all NMSC cases, respectively; other types of are extremely rare. The incidence of those varies, depending on the race, skin type, and geographic region, with a lower incidence in Asians compared with Caucasians. In general, NMSC has a favorable prognosis after local resection of the primary lesion. Reported rates of metastasis range between 0.0028% and 0.55% for BCC, while that for cSCC is 2.5%. Skin adnexal carcinomas are also considered to have a low metastatic potential. However, patients with metastatic disease have an extremely poor prognosis. The median overall survival (OS) of BCC patients is 10.0 months (range, 0.5–108.0 months), whereas those of cSCC and EMPD patients are 2.19 and 1.5 years, respectively.

Treatment of those advanced forms has long been done by the administration of cytotoxic chemotherapeutic agents. Patients with cSCCs are often treated with bleomycin, peplomycin, irinotecan, platinum, anthracyclines, taxanes, or 5-fluorouracil. For EMPDs, single-agent taxane, cisplatin, or fluoropyrimidine-based regimens are used. Nevertheless, evidence regarding the clinical benefit of these therapies is limited, mainly due to the rarity of these cancers and the challenges in the design of well-controlled clinical trials. Conducting clinical studies in patients with adnexal carcinomas is even more challenging, as the incidence of adnexal carcinoma is extremely low. The majority of commonly used cytotoxic agents have not gained regulatory approval for the treatment of metastatic malignant cutaneous epithelial tumors.

Increasing knowledge regarding cancer pathobiology, as well as advances in molecular biotechnology, have accelerated the development of targeted therapies. As for cSCC, the efficacy and safety of the monoclonal anti-epidermal growth factor receptor antibodies cetuximab and panitumumab and the orally administered small-molecule inhibitors gefitinib and erlotinib have been reported. Orally administered small-molecule inhibitors of the Hedgehog signal pathway, vismodegib and sonidegib, have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced BCCs. The anti-epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab was reported to provide a clinical benefit in patients with HER2-positive EMPD.

Monoclonal antibodies targeting immune checkpoint molecules have emerged as promising therapeutic approaches for several human cancers. Particularly, monoclonal antibodies targeting programmed cell death 1 (PD-1) and its ligand, programmed cell death ligand 1 (PD-L1), have revolutionized the landscape of malignant skin cancer. The PD-1/L1 pathway plays a critical role in tumor immune evasion across a broad range of tumor types. PD-1 is highly expressed in activated lymphocytes, whereas PD-L1 is expressed in cancer and stromal cells; binding of PD-L1 to PD-1 suppresses antitumor immune responses. Thus far, the FDA has approved the PD-1/PD-L1 inhibitors nivolumab and pembrolizumab for melanoma, cemiplimab for cSCC, and pembrolizumab and avelumab for Merkel cell carcinoma. However, no PD-1/PD-L1 inhibitors have been approved for use in cSCC patients in Japan. Furthermore, none of these agents are currently approved for rare adnexal tumors anywhere in the world.

To address these unmet medical needs, especially in Japanese patients with metastatic malignant cutaneous epithelial tumors, we designed a clinical trial to evaluate the efficacy and safety of nivolumab in Japanese patients with metastatic cSCC and other rare malignant cutaneous epithelial tumors.

2. Methods/design

2.1. Objectives, trial design, and study setting

This study is a single-arm, open-label, multi-institutional phase 2 clinical trial aiming to assess the efficacy and safety of nivolumab in patients with advanced cutaneous epithelial tumors. The recruitment of study participants started in July 2019 and will continue until a total of 30 participants are registered. The study will be conducted in 8 centers: Keio University Hospital, Tohoku University Hospital, Niigata Cancer Center Hospital, National Cancer Center Hospital, Nagoya University Hospital, Kyoto University Hospital, Wakayama Medical University Hospital, and National Hospital Organization Kyushu Cancer Center. All study participants are required to sign an informed consent form by the investigators. Nivolumab will be administered every 4 weeks for up to 26 cycles; the treatment will continue for up to 2 years in patients benefiting from the treatment who show no evidence of disease progression.

2.2. Eligibility criteria

2.2.1. Inclusion criteria.

1. Age: 20 years or older.
2. Histologically confirmed incurable, advanced, or recurrent epithelial skin malignancies after surgical treatment and/or radiotherapy.
3. ≥1 measurable lesions based on RECIST 1.1
4. ECOG performance status 0–1.
5. Life expectancy ≥90 days
6. Women willing to use double contraception and agree not to breastfeed for at least 5 months after final administration.
7. Men willing to use double contraception for at least 5 months after final administration.
8. Sufficient organ functions: all of the following conditions are fulfilled:
   - White blood cell ≥2000/mm³
   - Absolute neutrophil count ≥1500/mm³
   - Platelets ≥100,000/mm³
2.2.2. Exclusion criteria.

1. History of anaphylaxis to other antibody formulations, severe allergy, chronic or recurrent autoimmune disease, transplantation therapy, recent transient cerebral ischemic attack or cerebral vascular accident, recent thrombosis, or thromboembolism.
2. History of additional malignancy except for completely resected BCC, carcinoma in situ, intramuscular cancer, superficial bladder cancer, or other cancers that have not recurred for at least 5 years before enrollment.
3. History of pre-treatment using anti-PI3/L1/L2, anti-CD137, anti-CTLA-4 inhibitor or any other antibody or drugs intended for T-cell regulation.
4. Active central nervous system (CNS) metastases.
5. Uncontrolled tumor-associated pain.
6. Current disease; active autoimmune disease, diverticulitis or symptomatic peptic ulcer disease, pericardial effusion, pleural effusion or ascites requiring sustained treatment, uncontrollable diabetes mellitus, systemic infection requiring treatment, interstitial lung diseases, pulmonary fibrosis, or unstable radiation pneumonitis, uncontrollable or severe cardiovascular disease.
7. Recent following treatments within 28 days prior to the enrollment; systemic adrenocortical hormone, immunosuppressant, unapproved drugs, any antineoplastic agent, surgical adhesion of the pleura or pericardium, surgery under general anesthesia, radiotherapy.
8. Received surgery under local or topical anesthesia within 14 days prior to the enrollment.
9. Received any radiopharmaceuticals within 56 days prior to the enrollment.
10. Seropositive for HBsAg, HCV-Ab, or HIV-Ab.
11. Pregnant, breast-feeding or potentially pregnant.
12. History of any condition or therapy that might confound the results of this study.

2.2.3. Ethics approval and consent to participate. This study is being conducted in accordance with the principles expressed in the Declaration of Helsinki, good clinical practice guidelines and SPIRIT (Standard Protocol Items: Recommendations for Intervenional Trials) guidelines. The protocol version 1.0 was approved by the Institutional Review Board of Keio University Hospital in May 2019 and the institutional review board of the following participating center: Tohoku University Hospital, Niigata Cancer Center Hospital, National Cancer Center Hospital, Nagoya University Hospital, Kyoto University Hospital, Wakayama Medical University Hospital, and National Hospital Organization Kyushu Cancer Center. Written informed consent has been obtained from all enrolled participants.

2.2.4. Endpoints. The primary outcome of this study will be the response rate based on RECIST, version 1.1 criteria. Secondary outcome measures include the best overall response rate, progression-free survival (PFS), OS, disease control rate, and adverse events graded using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. For this study, PFS will be defined as the time from initiation of treatment in the clinical trial to disease progression or death from any cause, and OS will be defined as the time from initiation of treatment in the clinical trial to death from any cause. The response rate based on the immune RECIST will also be assessed as an exploratory outcome measure.

2.2.5. Treatment methods. The trial schedule is composed of 3 periods: the screening, treatment, and post-observation periods. The screening period starts from the date of consent acquisition to the day before the first administration of the study drug. During this screening period, inclusion/exclusion criteria for the study participants will be evaluated. During the treatment period, 480 mg nivolumab will be administered intravenously over 30 minutes, every 4 weeks. Administration of the study drug will be continued for up to 26 doses, with a maximum treatment period of 2 years. Study participants will be assessed for a tumor response every 2 treatment cycles by imaging. Any patients who meet the criteria for discontinuation of the treatment or who have completed the 2-year administration period will be assessed for a tumor response and move into the post-observation period. During the post-observation period, adverse events will be reported 28 days after the last dose of nivolumab. Subsequently, tumor lesions will be monitored every 8 weeks by imaging during the follow-up period. To determine OS, all subjects will be followed-up until death, withdrawal of consent, or the end of the study.

2.2.6. Criteria for discontinuation of the treatment. The administration of nivolumab will be discontinued in patients who experience at least 1 of the following:
1. a radiographic complete response according to the response evaluation criteria in solid tumors (RECIST) version 1.1, with the exception of cases with a high risk of recurrence;
2. radiographic disease progression according to the RECIST, version 1.1 or apparent disease progression with clinical symptoms;
3. grade 3 or higher interstitial pneumonia;
4. grade 2 or higher eye pain or blurred vision, regarded as a response to the study drug, showing no improvement to ≤ grade 1 after appropriate treatment;
5. grade 3 or higher bronchospasm, diarrhea, colitis, neurotoxicity, hypersensitive reaction, infusion reaction, or uveitis, regarded as a response to the study drug;
6. grade 3 or higher thrombocytopenia for ≥ 5 days;
7. more than 10 weeks from the start of the previous treatment cycle;
8. the investigator or physician decides to discontinue administration of the drug.

2.2.7. Concomitant medications. Medications specifically prohibited in the exclusion criteria will be not allowed during the ongoing trial. Patients are also prohibited from receiving the following therapies during the screening and treatment phase of the study:
• Any investigational medication other than the study drug.
• Any anticancer therapies including chemotherapy or biologic therapy other than the study medication, excluding the follows:
• Intravenous infusion of zoledronic acid hydrate, pamidronate disodium or subcutaneous injection of denosumab, started for bone metastases before enrollment in this study

Systemic steroid therapy can be combined when immune-related adverse events caused by the study drug are suspected.

2.2.8. Data collection. Data quality control will be conducted by a combination of centralized (remote) and on-site monitoring, according to each procedures standardized protocols. Centralized monitoring will be conducted by the coordinating investigator, the coordinating office, and the data center conducting the data collection. The data center will verify the progress of the clinical trial, the visit of each patient, protocol compliance, and the occurrence of adverse events. A centralized monitoring report will be created by the data center and submitted to the coordinating investigator, who will ensure that the study is conducted properly and safely based on the centralized monitoring report and will take appropriate measures when necessary.

The on-site monitoring will ensure that the study is conducted in compliance with the protocol and good clinical practice guidelines, as well as assess the electronic case report forms. The data manager will check for inconsistencies. The quality assurance auditor will assess the quality of the study independently according to the quality assurance plan. Moreover, the auditor will assess that the study is conducted in compliance with the protocol and good clinical practice guidelines.

2.2.9. Sample size calculation. Assuming a null hypothesis of a response rate of ≤5% and an alternative hypothesis of 25%, a minimum of 26 patients are required to achieve a 5% two-sided type I error and 80% power based on the exact binomial distribution. A target sample size of 30 was set to account for an expected patient dropout of 10%.

2.3. Statistical analysis

Statistical analyses and reporting will be conducted in accordance with the Consolidated Standards of Reporting Trials guidelines, with the primary analyses based on the intent-to-treat principle without imputing any missing observations. All efficacy analyses will be based primarily on the full dataset, which includes all patients who have received at least 1 dose of nivolumab and were in accordance with the study protocol. Safety analysis will be conducted using data from the safety analysis population. For baseline variables, summary statistics will be performed using frequencies and proportions for categorical data and means and standard deviations for continuous variables.

The primary endpoint for efficacy will be the proportion of responders, considering a response threshold of 5% (H₀, null hypothesis) and an expected response rate of 25% (H₁, alternative hypothesis). The 95% confidence intervals will be calculated according to the binomial distribution of the response rate. The confidence interval limits will be assessed against the response threshold.

Subgroup analysis will be performed to evaluate safety and efficacy depending on the tumor subtype. All statistical analyses will be performed using SAS software version 9.4 (SAS Institute). All statistical analyses will be described in detail in the statistical analysis plan, which will be fixed prior to database lock.

2.4. Confidentiality

All study-related information will be stored securely on-site and identified by a coded number only to ensure participant confidentiality. All records that contain names or other personal identifiers will be stored separately from study records identified by code number. All local databases will be secured with password-protected access systems. Data generated by this trial will be considered confidential by the investigators, except for data to be included in publications.

2.5. Patient and public involvement

No patient involved.

3. Discussion

This is a single-arm clinical trial that involves the use of nivolumab in Japanese patients with metastatic cSCC or other rare malignant cutaneous epithelial tumors. The rationale of this study relies on the several previous clinical and basic evidences (Table 1). In a phase I study assessing the usefulness of the PD-1 inhibitor cemiplimab in patients with metastatic and locally advanced cSCC, an overall response rate of 50% was reported. In a phase II study, the overall response rate was 47.5% (28/59 cases), including 4 cases of complete remission. By integrating the results of these 2 studies, the response rate of metastatic cSCC to cemiplimab was 46.7% (35/75 cases). The clinical benefit of anti-PD-1 antibodies for rare malignant cutaneous epithelial tumors have also been reported by several case reports. Successful treatment with nivolumab of advanced BCC patients refractory to Hedgehog signaling inhibitors has been reported. Another case report demonstrated that treatment with pembrolizumab resulted in a partial response in a patient with cutaneous apocrine carcinoma. The tumor mutation burden has been associated with the neoantigen burden and response to anti-PD-1 treatment in melanoma. Importantly, cSCCs are reported to have a high mutation burden among various cancer types. Furthermore,
some EMPD cases demonstrated a similar tumor mutation burden as that in SCC cases.\[^{46}\] Based on these clinical and biological observations, we hypothesize that nivolumab will also show a clinical benefit in multiple malignant cutaneous epithelial tumor types, regardless of any biological and pathological differences.

The fact that PD-1 inhibitors have gained regulatory approval for use in cSCC in the U.S. but not in Japan is mainly attributed to differences in the incidence of metastatic cSCCs. The incidence of cSCC in Caucasian populations is reported to be 17 to 360 per 100,000 cases, which is 5.8 to 138 times higher than that in Asian populations (2.6–2.9 per 100,000 cases).\[^{47}\] In a survey of the prevalence of advanced NMSCs in Japan, the annual reported number of advanced cSCC patients was 323.5.\[^{48}\] Nevertheless, the incidence of metastatic cSCC is increasing. The 5-year OS rate for use in Japanese patients with malignant cutaneous epithelial tumors, the treatment of which remains an unmet clinical need.

Because these tumor types are extremely rare, well-controlled clinical trials involving patients with such tumors are unlikely to be conducted.

This study design has several limitations, most of which are because of the rarity of the tumor types involved. The first, number of patients enrolled will be low, and the cancer type varies among the study participants. The second, heterogeneity in the response to nivolumab among the study participants are expected, due to potential differential sensitivity of the different cancer types to immunotherapy. Nevertheless, the present study could lead to the regulatory approval of nivolumab for use in Japanese patients with malignant cutaneous epithelial tumors, the treatment of which remains an unmet clinical need.

### 3.1. Trial status

The trial is currently actively recruiting patients. Completion of patient recruitment is expected for the beginning of 2021.

### Acknowledgments

We would like to thank all members of study operation office and data center.

### Author contributions

MI, JH and KT contributed to the writing of the manuscript. T. Fun is the principal investigator and responsible for the organization and coordination of the trial. All authors contributed to the management and administration of the trial. T.Fun conceived the idea for the project and designed the study.

**Conceptualization:** Takeru Funakoshi.

**Funding acquisition:** Takeru Funakoshi.

**Methodology:** Yasunori Sato.

**Project administration:** Takeru Funakoshi.

**Supervision:** Masayuki Amagai, Takeru Funakoshi.

**Writing – original draft:** Maki Ishii, Ikuko Hirai, Keiji Tanase.

**Writing – review & editing:** Ikuko Hirai, Keiji Tanase, Takayuki Fusumae, Yoshiho Nakamura, Keitaro Fukuda, Hiroshi Uchi, Kenji Kabashima, Atsushi Otsuka, Kenji Yokota, Naoya Yamazaki, Kenjiro Namikawa, Taku Fujimura, Tatsuya Takenouchi, Yuki Yamamoto, Mana Nishiguchi, Yasunori Sato, Masayuki Amagai.

### References

1. Buettner PG, Raasch BA. Incidence rates of skin cancer in Townsville, Australia. Int J Cancer 1998;78:587–93.
2. Palme CE, MacKay SG, Kalnins I, et al. The need for a better prognostic staging system in patients with metastatic cutaneous squamous cell carcinoma of the head and neck. Curr Opin Otolaryngol Head Neck Surg 2007;15:103–6.
3. Lo JS, Snow SN, Reizner GT, et al. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol 1991;24:715–9.
4. T, Eberle A, Nennecke A, et al. GEKID Cancer Survival Working Group. Survival with nonmelanoma skin cancer in Germany. Esemm N, Jansen L, Castro FA. Chen Br J Dermatol 2016;174:778–85.
5. Bernárdez C, Requena L. Treatment of malignant cutaneous adnexal neoplasms. Actas Dermosifiliogr 2018;109:63–23
6. Wysong A, Aani SZ, Tang JY. Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011. JAMA Dermatol 2013;149:615–6.
7. Zhu GA, Lynn Su Chang A. Overall and progression-free survival of stage 4 cutaneous squamous cell carcinoma at a single large referral center. J Am Acad Dermatol 2015;73:165–6.
8. Ohara K, Fujisawa Y, Yoshino K, et al. A proposal for a TNM staging system for extramammary Paget disease: retrospective analysis of 301 patients with invasive primary tumors. J Dermatol Sci 2016;83:234–9.
9. Bejar C, Maube E. Therapy of advanced squamous cell carcinoma of the skin. Curr Treat Options in Oncol 2014;15:302–20.
10. Cartei G, Cartei F, Interlandi G, et al. Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol 2000;23:181–4.
11. Report of Medical Research Council Working Party on Bleomycin . Bleomycin in advanced squamous cell carcinoma: a random controlled trial. Br Med J 1976;6003:188–90.
12. Sadek H, Azli N, Wending JL, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 1990;8:1692–6.
13. Wollina U, Hansel G, Koch A, et al. Oral capcetabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin. J Cancer Res Clin Oncol 2005;3:500–4.
14. Brewster AM, Lee JJ, Clayman GL, et al. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol 2007;15:1974–8.
15. Nakamura Y, Tanese K, Hirai I, et al. Carboplatin and etoposide combination therapy for advanced malignant epithelial skin tumors: retrospective study of six patients. J Dermatol 2018;45:874–5.
16. Ikeda S, Ishihara K, Matsunaka N. Peplomycin therapy for skin cancer in Japan. Drugs Exp Clin Res 1986;12:247–55.
17. Tokuda Y, Arakura F, Uhara H. Combination chemotherapy of low-dose 5-fluorouracil and cisplatin for advanced extramammary Paget's disease. Int J Clin Oncol 2015;20:194–7.
18. Oashi K, Tsutsumida A, Namikawa K, et al. Combination chemotherapy for metastatic extramammary Paget disease. Br J Dermatol 2014;170:1354–7.
19. Yoshino K, Fujisawa Y, Kiyohara Y, et al. Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary Paget's disease. J Dermatol 2016;43:633–7.
20. Mikoshiba Y, Uharu H, Kubo H, et al. S-1 induced a durable response in metastatic extramammary Paget's disease. J Dermatol 2013;40:664–5.
21. Kato J, Hida T, Yamashita T, et al. Successful TS-1 monotherapy as the second-line treatment for advanced extramammary Paget's disease: a report of two cases. J Dermatol 2018;45:80–2.
22. Matsushita S, Yonekura K, Mera K, et al. Successful combination chemotherapy in two patients with metastatic extramammary Paget disease. J Dermatol 2011;38:996–8.
23. Ogata D, Hokama Y, Tsuchida T. Successful treatment of bilateral multiple lymph node metastases in extramammary Paget's disease with surgery and sequential chemotherapy of S-1 and docetaxel. J Dermatol 2015;42:1193–4.
24. Egashira S, Kajihara L, Kanemaru H, et al. Achieved good response of S-1 and docetaxel combination chemotherapy in two patients with metastatic extramammary Paget's disease. J Dermatol 2017;44:e103–4.
Ishii et al. Medicine (2020) 99:44

[25] Hirai I, Tanese K, Nakamura Y, et al. Combination cisplatin-epirubinc-paclitaxel therapy for metastatic extramammary Paget's disease. Oncologist 2019;24:e384–6.

[26] Reigneau M, Robert C, Routier E, et al. Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unsectable advanced nonmetastatic cutaneous squamous cell carcinomas. Br J Dermatol 2015;173:527–34.

[27] Foote MC, McGrath M, Guminski A, et al. Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol 2014;25:2047–52.

[28] William WN Jr, Feng L, Ferrarotto R, et al. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: a single-arm phase II clinical trial. J Am Acad Dermatol 2017;77:1110–3.

[29] Gold KA, Kies MS, William WN, et al. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. Cancer 2018;124:2169–73.

[30] Basset-Séguin N, Hauschild A, Kunzendorf F, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer 2017;86:334–48.

[31] Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase II trial. Lancet Oncol 2015;16:716–28.

[32] Dummer R, Guminski A, Gutzmer R, et al. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): a phase II, randomised, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol 2016;75:113–23.

[33] Xie P, Lefrançois P. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis. J Am Acad Dermatol 2018;79:1089–100.

[34] Wakabayashi S, Yoneyama K, et al. Dramatic clinical response of relapsed metastatic extramammary Paget's disease to trastuzumab monotherapy. Case Rep Dermatol Med 2015:10.9524/2015/2015:51.

[35] Hanawa F, Inozume T, Harada K, et al. A case of metastatic extramammary Paget's disease responding to trastuzumab plus paclitaxel combination therapy. Case Rep Dermatol 2011;3:223–7.

[36] Barth P, Dulaaim Al-Saleem E, Edwards KW, et al. Metastatic extramammary Paget's disease of scrotum responds completely to single agent trastuzumab in a hemodialysis patient: case report, molecular profiling and brief review of the literature. Case Rep Oncol Med 2015:10.1155/2015/695189.

[37] Ikeda S, Goodman AM, Cohen PR, et al. Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. NPJ Genom Med 2016;1:16037.

[38] Gentzler R, Hall R, Kunk PR, et al. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. Immunotherapy 2016;8:583–600.

[39] Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99:12293–7.

[40] Migden MR, Ruscin D, Schmitts CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous-squamous-cell carcinoma. N Engl J Med 2018;379:341–51.

[41] Ikeda S, Goodman AM, Cohen PR, et al. Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. NPJ Genom Med 2016;1:16037.

[42] Rogatsch M, Schmid J, Lax S, et al. Metastatic cutaneous apocrine adenoacarcinoma responsive to the programmed cell death protein 1 inhibitor pembrolizumab. Eur J Cancer 2018;50:146–8.

[43] Ruiz NA, Hellman MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124–8.

[44] Pickering CR, Zhou JH, Lee JJ, et al. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer. Br J Dermatol 2017;176:498–502.

[45] Chang ALS, Tran DC, Cannon JGD, et al. Pembrolizumab for advanced non-melanoma skin cancers treated at dermatology departments in Japan. J Dermatol Sci 2018;92:230–6.

[46] Ogata D, Namikawa K, Otsuka M, et al. Systemic treatment of patients with advanced cutaneous squamous cell carcinoma: response rates and outcomes of the regimes used. Eur J Cancer 2020;127:108–17.

[47] Zhu Z, Zhao L, Wang X, et al. Whole-exome sequencing reveals frequent mutations in chromatin remodeling genes in mammary and extramammary Paget's diseases. J Invest Dermatol 2019;139:789–95.

[48] Glotzer HM Jr, Neal K. Skin cancer in skin of color. J Am Acad Dermatol 2006;55:741–60. quiz 761–764.

[49] Fujisawa Y, Funakoshi T, Nakamura Y, et al. Nation-wide survey of advanced non-melanoma skin cancers treated at dermatology departments in Japan. J Dermatol Sci 2018;92:230–6.

[50] Ogata D, Namikawa K, Otsuka M, et al. Systemic treatment of patients with advanced cutaneous squamous cell carcinoma: response rates and outcomes of the regimes used. Eur J Cancer 2020;127:108–17.

[51] Maubec E, Bouhaya M, Petrow P, et al. Pembrolizumab as first-line therapy in patients with unsectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN. J Clin Oncol 2019;37:9547.

[52] Berkel DJ, Ragab OM, Huggins S, et al. PD-1 inhibition in cutaneous squamous cell carcinoma (cSCC). 2018 ASCO Annual Meeting Abstracts. J Clin Oncol 2018;36: abstr e15100.

[53] Chang ALS, Tran DC, Cannon JGD, et al. Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. J Am Acad Dermatol 2019;80:564–6.